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Letter in response to Chitale et al.: determining the
utility of the 60-minute cortisol measurement in the
short synacthen test
Dear Editors,
We read with interest the paper by Chitale et al.1 and agree
that the 60-minute sample is essential to the standard 250-mcg
short synacthen test (SSST), in contrast to the low-dose short
synacthen tests (LDSSTs), and welcome any research helping to
clarify the optimal use of the short synacthen test in terms of
dose, sampling times and diagnostic cut-offs.
A recent survey of UK paediatric endocrinologists demonstrated
82% using a form of LDSST and 87% the SSST. All centres (N = 39)
sampled at 0 and 30 minutes but 18% did not perform a 60-minute
sample. There were a number of additional samples taken at differ-
ent time points, with a mean of 38 samples per SSST for all centres.2
In keeping with national practice, our tertiary paediatric endo-
crinology service is predominantly performing LDSST; however,
on analysis of the SSSTs undertaken between January 2011 and
May 2012 (N = 20), we have found similar results to Chitale et al.
in our paediatric cohort. Of the 20 tests analysed, the 60-minute
cortisol value was higher than the 30-minute sample in 90%, on
average 841 nmol/l higher (SD 706 nmol/l) supporting the use
of a 60-minute sample to guard against false-positive results.
Discrepant results, that is, those where the patient would be felt
to have adrenal insufficiency based on the 30-minute cortisol
value but not on the 60-minute result or vice versa depend on the
cut-off value applied. Our national survey revealed that 54% of
responding centres use 500 nmol/l and 44% 550 nmol/l.2 Employ-
ing a cut-off of 500 nmol/l, 32% of our patients undergoing an
SSST would have been misdiagnosed with adrenal insufficiency
without the 60-minute sample and 10% using 550 nmol/l. In con-
junction with our laboratory colleagues, we have recently revised
our diagnostic cut-off to 450 nmol/l following the introduction of
a new cortisol assay and welcome the authors’ view that local ref-
erence ranges need to be determined rather than historically set
values that may not reflect laboratory advances and variability.
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An oncocytic adrenal tumour in a patient with
Birt-Hogg-Dube syndrome
A 62-year-old female patient was initially diagnosed with a histo-
logically confirmed trichodiscoma. Due to the association of
trichodiscomas with Birt-Hogg-Dube Syndrome (BHD), the
patient underwent screening for renal tumours, which revealed a
heterogeneous right adrenal mass (Fig. 1a). The patient did not
have any clinical hormone excess. Adrenalectomy revealed a
tumour measuring 62 cm and weighing 104 g with features diag-
nostic for an adrenal oncocytoma (Fig. 1b). While the tumour did
not fulfil the established criteria for malignancy in oncocytic adre-
nal neoplasms, the borderline Ki67 labelling of 5% suggested the
diagnosis of at least uncertain malignant behaviour rather than a
benign lesion.1 The traditional Weiss scoring system to differenti-
ate benign and malignant lesion fails in oncocytomas as they
almost invariably are positive for at least two of the criteria, lead-
ing to overdiagnosis of malignant lesions.1 The patient remains
disease-free 24 months following surgery. Review of a chest CT
imaging revealed two small cysts. The patient’s family history was
suggestive of BHD, with a maternal cousin with a history of
spontaneous pneumothorax (Fig. 1c). The patient’s mother had a
diagnosis of basal cell carcinoma and one maternal aunt died of
lung cancer. The patient’s father died of pancreatic cancer. The
patient underwent germline genetic testing, revealing a deleterious
mutation in exon 11 of FLCN (c.1252delC; p.Leu418TrpfsX50)
leading to a premature stop codon and confirming the diagnosis
of BHD. Unfortunately, insufficient tumour tissue precluded loss
of heterozygosity analysis.
Adrenocortical tumours, benign and malignant, are well
known to occur as part of hereditary cancer susceptibility
syndromes.2 Adrenocortical carcinoma (ACC) is a core malig-
nancy of Li Fraumeni syndrome. ACC and adrenocortical
adenomas are observed in Beckwith Wiedemann syndrome,
Multiple Endocrine Neoplasia type 1 and Familial Adenomatous
Polyposis. Oncocytic adrenal tumours are rare, have biological
behaviour, which can be difficult to predict and have not been
reported in association with hereditary syndromes.1
Birt-Hogg-Dube Syndrome was first described in 1977 with the
classical manifestations of benign hair follicle-associated tumours.
In the decades to follow, BHD has been defined as an autosomal
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dominant hereditary syndrome, characterized by the cutaneous
triad of fibrofolliculomas, trichodiscomas and acrochordons, lung
cysts and renal tumours. BHD is caused by mutations in FLCN
(Online Mendelian Inheritance in Man #13510, http://omim.org/
entry/135150, for photograph of typical skin lesions see Ref. 3).
Renal oncocytomas, as well as chromophobe and mixed chromo-
phobe oncocytic renal tumours, are typical for BHD.3
In order to explore an adrenal phenotype in BHD patients,
we identified 14 patients from 11 unique families with geneti-
cally confirmed FLCN mutations in the University of Michigan
Cancer Genetics Registry. A stable 12 cm adrenal nodule was
observed in a 22-year-old male patient. Next, we retrospectively
reviewed 359 patients diagnosed with ACC using the Michigan
Endocrine Oncology Repository. None of the 359 patients had
reported history of trichodiscoma or fibrofolliculoma. One
patient reportedly had two lung cysts sized 12 cm. Three
patients had histories of renal tumours, including one oncocy-
toma. Five patients reported first-degree relatives with kidney
cancer. No patient fulfilled clinical criteria for BHD, had under-
gone germline genetic testing for FLCN mutations or had a
reported family history of BHD. In summary, adrenal tumours
may be more common in BHD patients, but BHD is not com-
mon amongst ACC patients.
Review of the literature yielded three reports of adrenal
tumours in BHD patients. First, a study of 23 BHD patients
with confirmed FLCN mutations presenting with lung cysts
reported one patient with an adrenal nodule.4 This adrenal
nodule was small (15 9 20 cm) and nonhormone-secreting
(Seyama K, pers. comm.). Second, Juszczak et al. reported a
large oncocytic adrenal tumour in a 36-year-old female patient
with BHD and confirmed FLCN mutation.5 The third report of
an adrenal tumour describes a presumed ectopic renal tumour
in the adrenal gland of a BHD patient.6
Our case, together with the case described by Juszczak et al.,
suggests that adrenal oncocytomas might be part of the BHD
tumour spectrum. With the exception of trichodiscoma, fibro-
folliculoma and typical kidney tumours, no specific association
of other tumours with BHD has been proven, despite several
reports of benign and malignant tumours in BHD patients.3 As
is often the case with rare cancer susceptibility syndromes, pre-
disposition to tumours other than the core malignancies is not
well defined. Furthermore, the phenotype of BHD can be subtle,
leading to underdiagnosis. Suspicion of BHD should be raised in
patients with adrenal oncocytomas. Dermatologic exam and
review of chest imaging can reveal other hallmark clinical
features of BHD.
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Fig. 1 (a) heterogeneous adrenal mass on T1
weighted MRI. (b) oncocytic adrenal neoplasm
with diffuse growth pattern. (c) Pedigree. Proband
(III.1) indicated with the arrow. A maternal cousin
fulfilled clinical criteria for BHD (III.3), making the
patient’s mother (II.3) and aunt (II.4) obligate
carriers.
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Functional consequences of a novel point mutation
in the CYP21A2 gene identified in a Chinese Han
patient with nonclassic 21-hydroxylase deficiency
Dear Sir,
Most of patients with 21-hydroxylase deficiency (21-OHD) are
compound heterozygotes or homozygotes, but heterozygous
carriers for CYP21A2 mutations and even no disease-causing
mutations in the CYP21A2 allele have been detected in some
patients with clinically and biochemically diagnosed 21-OHD.
Recently, we indentified a novel point mutation c.446 G>C
(p.R149P) in exon 4 in a female patient with hyperandrogenism
and her father. The patient came from a family of consanguine-
ous marriage and saw an endocrinologist at age 34 because of
infertility. She had an uneventful history and her karyotype was
46 xx. Hormonal determinations demonstrated elevated levels of
ACTH 2242 (normal range, 16–139 pM), total testosterone
701 (normal range, 045-375 nM). Both basal and ACTH stim-
ulated 17-OHP concentrations were 591 and 1057, respectively
(reference value in female, 13  025 nM). The levels of plasma
cortisol were normal. Her father has no clinical symptoms of
endocrine and reproductive diseases, and his serum level of
17-OHP was 742 (reference value in male, 35  12 nM).
Specific amplification of CYP21A2 by PCR was performed
from the 5′regulatory region (c. 710) to the end of translation,
followed by direct sequencing. The 46 to 56 kb and 26
to 28 kb upstream of CYP21A2, which was considered as a
potential regulation region, were also investigated.1 We did not
detect any mutation except the p.R149P. This mutation was
absent in 300 unrelated individuals (600 unrelated alleles) from
a Chinese Han control cohort. Moreover, we sequenced
CYP11B1 and 3b-HSD2 genes and found no mutations.
The human full-length CYP21A2-cDNA fragment was synthe-
sized from the pGEM3Z-CYP21 that had been kindly provided
by Dr Miller and was recloned into the HindIII/BamHI restric-
tion site of the pcDNA3.1 eukaryotic expression vector, resulting
in the pcDNA3.1-CYP21A2-WT construct. The mutagenesis
were performed from the pcDNA3.1-CYP21A2-WT construct,
using the fast-mutagenesis system (TransGen Biotech Co., Ltd,
Beijing, China), and were checked by sequencing the entire con-
structs. Enzyme activity was analysed by taking the activity of
wild-type as 100%, pcDNA3.1 alone as 0. The mutation p.P30L
(c.39C>T) was analysed as a control under the same conditions.
The mutant p.R149P enzyme showed a residual CYP21 activity
of 169  20% for the conversion of progesterone and
234  17% for the conversion of 17-hydroxyprogesterone,
much lower than the mutation p.P30L enzyme. Michaelis–
Menten constant (Km) values revealed that both mutated
proteins had a markedly decreased affinity for the two kinds of
substrates compared with wild-type. The maximal velocity
(Vmax) of p.P30L mutation was higher than p.R149P, although
they both were slower than wild-type (Table 1). Analysis of
Table 1. Apparent kinetic constants for the CYP21 Wild Type and
mutant proteins
Wild Type P30L R149P
17-hydroxyprogesterone
Km (lM) 02  01 04  01 048  006
Vmax (pmol/min1/mg1) 278  13 178  09 985  025
Vmax/Km 1323 405 205
Progesterone
Km (lM) 04  02 13  03 12  02
Vmax (pmol/min1/mg1) 346  28 240  15 93  04
Vmax/Km 871 183 81
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